{"id": "patient_01_q0", "generated_text": "D: Vincristine\n\nVincristine is not part of the current treatment regimen for Mrs. Sample's DLBCL. The context clearly states the current treatment regimen which includes:\n\n- Polatuzumab vedotin:", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q1", "generated_text": "D: She has 3-vessel CHD. is NOT accurate based on the provided information. The text for option D: She has 3-vessel CHD. is NOT accurate based on the provided information. : She has 2-v", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q2", "generated_text": "A: Mrs. Sample suffers from primary progressive type of multiple sclerosis. This is mentioned in the medical history where it is stated: \"Other diagnoses\" include \"Primary progressive type of multiple sclerosis (ID 03/02)\". To my knowledge", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q3", "generated_text": "B: The patient takes Fingolimod (GilenyaÂ®) 0.5 mg: Take 1 capsule in the bedtime, Note: Take a break as directed. B: Text for option A\nThe text mentions that the", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q4", "generated_text": "D: Oncology board recommended 6 cycles of R-Pola-CHP for Mrs. Sample. The patient was also advised to pause fingolimod re-evaluation in 4-5 months, continue therapy near residence in the clinic,", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q5", "generated_text": "C: The metastasis was located in the thoracic vertebra 10 (T10) as indicated in the pathology report where it states \"Tumor cuff T10. dignity? Entity? Macroscopy: 1st lamina", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q6", "generated_text": "A: The CT scan of Mrs. Sample's whole body on 01/09/2017 used Omnipaque 320 for contrast enhancement. This is indicated in the context provided, where it states \"Omn", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q7", "generated_text": "B: The patient underwent an MR Head on 12/19/2016, an MR Spine plain + post-contrast on 12/20/2016, a CT Thoracic Spine on", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q8", "generated_text": "E: The patient started taking 2mg of Melatonin in the evening. \n\nThis answer is derived from the medication list provided for both admission and discharge. The dosage of Melatonin was noted to be 2mg (sustained-release)", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
{"id": "patient_01_q9", "generated_text": "B: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake.\n: The patient's pain management was escalated, as indicated by an increased frequency of Hydromorphone intake. The dosage of", "model_name": "Qwen/Qwen2.5-3B-Instruct", "generation_params": {"temperature": 0.7, "max_new_tokens": 50, "top_p": 0.9, "index": 0}}
